Search

everythinglearnresearchcommunity

for

Search:↓

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Blocking the protein CXCL12 with a specific antibody can increase hair growth in common hair loss conditions.

Immune cell-targeting biologics show potential for treating alopecia areata but need better-targeted therapies.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.

Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.

Auto-antibody testing is a useful but not definitive tool in diagnosing interstitial lung diseases, and using a specific algorithm could make testing more cost-effective.

Targeted protein degraders show promise in treating cancer but need to target more diverse proteins.

Anti-CD19 therapy may help treat SLE and NMOSD.

Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

A new method speeds up insulin amyloid fibril growth, useful for studying diseases.

Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.

Raltitrexed conjugates are less potent than the free drug but more effective at high concentrations.

The TCL1 transgenic mouse model is useful for understanding human B-cell leukemia and testing new treatments.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Janus kinase inhibitors are effective and safe for treating Alopecia Areata.

Combining specific nanoparticles with immune therapy significantly improves cancer treatment.

Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.

Adalimumab helped control a child's severe eye disease when other treatments failed.

Abrocitinib effectively treats severe alopecia areata with significant improvement and no side effects.

Researchers created a new mouse model for studying Citrullinemia Type I and similar conditions, showing symptoms and treatment responses like those in humans.

New markers can detect tumors, aid drug delivery, and treat cancer effectively and safely.

The photolyase-based device significantly changed the size and heat of potential skin cancer areas in patients.

Using 5-α-reductase inhibitors before treatment improves outcomes for patients with metastatic renal cell carcinoma.

Alopecia areata involves unique activation of certain immune cells.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.